TickerHumNYSE · Healthcare · Drug Manufacturers—General
Johnson & Johnson (JNJ)
As of Nov 11, 1:50 PM ET, Johnson & Johnson (JNJ) last traded at $278.45, down 0.83% on the day. Its TickerHum research score is 60/100 (above average). It reported revenue of $99.34B for the twelve months ending 2026-09-27, up 7.8% year over year.
Ratings
- Valuation: 52/100 — Strongest input: price / sales (ttm) 6.7x. Weakest: price / earnings (ttm) 42.3x.
- Growth: 22/100 — Strongest input: revenue growth (ttm, yoy) +7.8 %. Weakest: diluted eps growth (ttm, yoy) -36.4 %.
- Profitability: 78/100 — Strongest input: gross margin 67.6 %. Weakest: net margin 16.2 %.
- Financial health: 42/100 — Strongest input: long-term debt / equity 0.44. Weakest: current ratio 1.02.
- Momentum: 73/100 — Strongest input: 1-year return +43.2 %. Weakest: 3-month return +6.2 %.
- Attention: 50/100 — Strongest input: headlines in the last 7 days 57. Weakest: volume vs 3-month average 0.3x.
- Risk resilience: 90/100 — Strongest input: annualised volatility (1y) 21.1 %. Weakest: max drawdown (1y) -11.0 %.
- Data confidence: 98/100 — Strongest input: quote age (hours) 0 h. Weakest: inputs available 95 %.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $99.34B | TTM ending 2026-09-27 · 10-Q |
| Revenue growth | 7.8% | TTM ending 2026-09-27 · 10-Q |
| Net income | $16.1B | TTM ending 2026-09-27 · 10-Q |
| Diluted EPS | $6.58 | TTM ending 2026-09-27 · 10-Q |
| Gross margin | 67.6% | TTM ending 2026-09-27 · 10-Q |
| Net margin | 16.2% | TTM ending 2026-09-27 · 10-Q |
| Free cash flow | $20.59B | TTM ending 2026-09-27 · 10-Q |
| Cash | $16.91B | as of 2026-09-27 · 10-Q |
| Long-term debt | $35.8B | as of 2026-09-27 · 10-Q |
| Debt / equity | 0.44 | as of 2026-09-27 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0000200406).
Comparable companies for Johnson & Johnson
Selected by industry, business overlap and scale; these are not necessarily direct competitors.
- Johnson & Johnson vs AbbVie (JNJ vs ABBV) — Same industry (Drug Manufacturers—General); market cap 0.77x
- Johnson & Johnson vs Merck & Co. (JNJ vs MRK) — Same industry (Drug Manufacturers—General); market cap 0.54x
- Johnson & Johnson vs Eli Lilly and (JNJ vs LLY) — Same industry (Drug Manufacturers—General); market cap 2.0x
- Johnson & Johnson vs Amgen (JNJ vs AMGN) — Same industry (Drug Manufacturers—General); market cap 0.38x
- Johnson & Johnson vs Gilead Sciences (JNJ vs GILD) — Same industry (Drug Manufacturers—General); market cap 0.31x
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.